![Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study - The Lancet Oncology Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study - The Lancet Oncology](https://www.thelancet.com/cms/asset/68d4b7e3-b891-4491-9ab0-cbba4b4030a2/gr1.jpg)
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study - The Lancet Oncology
![FRONTLINE Combo, 1 Pipetta, Antiparassitario per Gatti, Gattini e Furetti di Lunga Durata, Protegge da Pulci, Zecche, Uova, Larve e Anche la Casa, Antipulci In Confezione da 1 Pipetta da 0.5 ml : FRONTLINE Combo, 1 Pipetta, Antiparassitario per Gatti, Gattini e Furetti di Lunga Durata, Protegge da Pulci, Zecche, Uova, Larve e Anche la Casa, Antipulci In Confezione da 1 Pipetta da 0.5 ml :](https://m.media-amazon.com/images/I/81QEZ9XrquL._AC_UF1000,1000_QL80_.jpg)
FRONTLINE Combo, 1 Pipetta, Antiparassitario per Gatti, Gattini e Furetti di Lunga Durata, Protegge da Pulci, Zecche, Uova, Larve e Anche la Casa, Antipulci In Confezione da 1 Pipetta da 0.5 ml :
![Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial - The Lancet Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial - The Lancet](https://www.thelancet.com/cms/asset/d21b0488-8d13-4c75-86eb-0bb2a98f8b88/gr1.jpg)
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial - The Lancet
![Harry Kane becomes England's all-time record scorer in qualifier win over Italy | Euro 2024 qualifying | The Guardian Harry Kane becomes England's all-time record scorer in qualifier win over Italy | Euro 2024 qualifying | The Guardian](https://i.guim.co.uk/img/media/e427faf8d8ec430068343b9022c44fa5ed0e96c6/0_36_3500_2100/master/3500.jpg?width=1200&quality=85&auto=format&fit=max&s=0345079e624d98f0c18f1c59b4f94839)
Harry Kane becomes England's all-time record scorer in qualifier win over Italy | Euro 2024 qualifying | The Guardian
![Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial - The Lancet Oncology Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/f0a7ba64-a0fc-4e7f-8966-c1723493d832/gr1.jpg)
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial - The Lancet Oncology
![The rapid spread of SARS-COV-2 Omicron variant in Italy reflected early through wastewater surveillance - ScienceDirect The rapid spread of SARS-COV-2 Omicron variant in Italy reflected early through wastewater surveillance - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0048969722028649-ga1.jpg)
The rapid spread of SARS-COV-2 Omicron variant in Italy reflected early through wastewater surveillance - ScienceDirect
![Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study - The Lancet Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study - The Lancet](https://www.thelancet.com/cms/asset/aee99cbc-80a0-49e4-9ac3-6cc4f16265f9/gr1.jpg)
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study - The Lancet
![Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial | Nature Medicine Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-01829-9/MediaObjects/41591_2022_1829_Fig1_HTML.png)
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial | Nature Medicine
![Compound flood hazard at Lake Como, Italy, is driven by temporal clustering of rainfall events | Communications Earth & Environment Compound flood hazard at Lake Como, Italy, is driven by temporal clustering of rainfall events | Communications Earth & Environment](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs43247-022-00557-9/MediaObjects/43247_2022_557_Fig1_HTML.png)
Compound flood hazard at Lake Como, Italy, is driven by temporal clustering of rainfall events | Communications Earth & Environment
![FRONTLINE Combo, 3 Pipette, Antiparassitario per Gatti, Gattini e Furetti di Lunga Durata, Protegge da Pulci, FRONTLINE Combo, 3 Pipette, Antiparassitario per Gatti, Gattini e Furetti di Lunga Durata, Protegge da Pulci,](https://m.media-amazon.com/images/I/81TT1ubwdjL.jpg)
FRONTLINE Combo, 3 Pipette, Antiparassitario per Gatti, Gattini e Furetti di Lunga Durata, Protegge da Pulci,
![Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 ... Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 ...](https://www.thelancet.com/cms/attachment/93c792df-ed55-48cd-905b-99101c6f5324/gr1.gif)